Summit Therapeutics Inc (SMMT)

04:43 AM

Summit Therapeutics (SMMT) asks shareholders to approve 8M-share Plan increase - Stock Titan

04:43 AM

11:01 AM

What makes Summit Therapeutics (SMMT) one of the best large caps under $30 - MSN

11:01 AM

04:02 AM

Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - MSN

04:02 AM

Apr 05, 2026

Chart Watch: Whats next for Summit Therapeutics Inc stockEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks

Apr 04, 2026

Apr 04, 2026

We're Not Very Worried About Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Rate - Moomoo

Apr 04, 2026

Apr 03, 2026

Does Summit Therapeutics (SMMT) Expanding Ivonescimab Trials Clarify Its Single-Asset Oncology Strategy? - simplywall.st

Apr 03, 2026

Apr 03, 2026

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - AOL.com

Apr 03, 2026

Apr 03, 2026

(SMMT) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 03, 2026

Apr 02, 2026

Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo

Apr 02, 2026

Apr 02, 2026

Summit plunges 80 percent after muscle-wasting disorder drug fails - AOL.com

Apr 02, 2026

Apr 02, 2026

SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill

Apr 02, 2026

Apr 01, 2026

Assenagon Asset Management S.A. Invests $1.04 Million in Summit Therapeutics PLC $SMMT - marketbeat.com

Apr 01, 2026

Mar 31, 2026

$Summit Therapeutics (SMMT.US)$ - Moomoo

Mar 31, 2026

Mar 31, 2026

Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Recommendation of "Moderate Buy" by Analysts - marketbeat.com

Mar 31, 2026

Mar 31, 2026

Barclays Maintains Summit Therapeutics (SMMT) Underweight Recommendation - MSN

Mar 31, 2026

Mar 31, 2026

Barclays Remains a Hold on Summit Therapeutics (SMMT) - The Globe and Mail

Mar 31, 2026

Mar 30, 2026

Aug Retail: Is Summit Therapeutics Inc undervalued by DCF analysisGap Down & Weekly Sector Rotation Insights - baoquankhu1.vn

Mar 30, 2026

Mar 30, 2026

Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18 - Moomoo

Mar 30, 2026

Mar 29, 2026

Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA - Sahm

Mar 29, 2026

Mar 29, 2026

Summit Therapeutics stock drops 3.94% as FDA accepts BLA for Ivonescimab in NSCLC - Traders Union

Mar 29, 2026

Mar 28, 2026

A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing - finance.yahoo.com

Mar 28, 2026

Mar 28, 2026

Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA FilingWhat's Changed - Yahoo Finance

Mar 28, 2026

Mar 27, 2026

Summit Therapeutics (SMMT) climbs 15.4% ahead of pipeline Q2 updates - msn.com

Mar 27, 2026

Mar 27, 2026

Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN

Mar 27, 2026

Mar 27, 2026

Summit Therapeutics to present ivonescimab data at ELCC 2026 - StreetInsider

Mar 27, 2026

Mar 27, 2026

Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026 - marketscreener.com

Mar 27, 2026

Mar 27, 2026

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 - Business Wire

Mar 27, 2026

Mar 27, 2026

Summit lung cancer drug showed 10.1-month brain PFS in Phase III - Stock Titan

Mar 27, 2026

Mar 26, 2026

Summit Therapeutics (NASDAQ:SMMT) Raised to Strong-Buy at Truist Financial - MarketBeat

Mar 26, 2026

Mar 26, 2026

What Makes Summit Therapeutics (SMMT) One of the Best Large Caps Under $30 - Insider Monkey

Mar 26, 2026

Mar 26, 2026

Aug Sectors: Can Summit Therapeutics Inc be the next market leader - baoquankhu1.vn

Mar 26, 2026

Mar 26, 2026

5 Large Cap Stocks Under $30 With Huge Upside Potential - Insider Monkey

Mar 26, 2026

Mar 25, 2026

Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates - Insider Monkey

Mar 25, 2026

Mar 25, 2026

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool

Mar 25, 2026

Mar 25, 2026

U.S. Markets Rose Wednesday; Summit Therapeutics Topped Leaders - Barron's

Mar 25, 2026

Mar 25, 2026

Summit Therapeutics Enters Strong Growth Phase Amid Partnerships and Trials - StocksToTrade

Mar 25, 2026

Mar 25, 2026

Summit Therapeutics (NASDAQ:SMMT) Trading 12.1% HigherHere's What Happened - marketbeat.com

Mar 25, 2026

Mar 25, 2026

Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN

Mar 25, 2026

Mar 24, 2026

Summit Therapeutics (SMMT) Stock Price Prediction for 2026, 2030-2040 - Traders Union

Mar 24, 2026

Mar 24, 2026

347,241 Shares in Summit Therapeutics PLC $SMMT Acquired by Tudor Investment Corp ET AL - marketbeat.com

Mar 24, 2026

Mar 23, 2026

Responsive Playbooks and the SMMT Inflection - Stock Traders Daily

Mar 23, 2026

Mar 23, 2026

Trade Recap: Does Summit Therapeutics Inc have a sustainable dividend2026 Investor Takeaways & Reliable Volume Spike Trade Alerts - baoquankhu1.vn

Mar 23, 2026

Mar 21, 2026

Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - The Globe and Mail

Mar 21, 2026

Mar 20, 2026

SMMT PE Ratio & Valuation, Is SMMT Overvalued - Intellectia AI

Mar 20, 2026

Mar 19, 2026

Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent

Mar 19, 2026

Mar 17, 2026

Jefferies downgrades Summit Therapeutics (SMMT) - MSN

Mar 17, 2026

Mar 16, 2026

Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile? - simplywall.st

Mar 16, 2026